● Recruiting

Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Patients With High - Risk Localized Prostate Cancer (DESAR-H)

Condition: High Risk Prostate Carcinoma · Sponsor: Samsung Medical Center

PhasePhase 2

Planned participants33

Who can joinMale, 20 Years to no upper limit

Healthy volunteersNo

About this study

Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients who underwent low-fractionation curative radiation therapy and hormone therapy

This description comes directly from the study's public registry record.

Talk to the study team

Won Park, M.D., Ph.D. · +82-2-3410-2616 · wonro.park@samsung.com

Always discuss trial participation with your own doctor first.

Locations (1)

Samsung Medical Center

Seoul, South Korea

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06461793